fogsprayhk
B7-33 | CAS 1818415-56-3 | RXFP1 Agonist and Anti-Fibrotic Relaxin Mimetic
Product Description
B7-33 is a single-chain relaxin mimetic peptide that functions as a selective agonist of the relaxin family peptide receptor 1 (RXFP1). It was rationally designed to mimic the biological actions of human relaxin-2 (H2 relaxin), a peptide hormone known for its potent anti-fibrotic, vasodilatory, and cardioprotective properties.
Unlike natural H2 relaxin, which is a two-chain peptide connected by disulfide bridges, B7-33 adopts a simplified single-chain structure. This modification enhances its synthetic stability, cost-efficiency, and bioavailability, while maintaining receptor selectivity.
Structural and Functional Background
Relaxin signaling through RXFP1 regulates fibrosis, inflammation, and tissue remodeling. The B7-33 peptide was developed to retain the beneficial effects of relaxin but minimize its complexity and off-target effects. By selectively activating the pERK1/2 pathway instead of the canonical cAMP pathway, B7-33 achieves targeted anti-fibrotic outcomes without triggering hormonal side effects.
B7-33 has demonstrated efficacy in reducing fibrosis, improving cardiac function, and promoting endothelial repair across several preclinical models.
Key Research Applications
Anti-Fibrotic Studies: Inhibits myofibroblast differentiation, decreases collagen synthesis, and reverses established fibrosis.
Cardioprotection: Enhances myocardial recovery following ischemic injury, attenuates remodeling, and reduces cardiac hypertrophy.
B7-33 | CAS 1818415-56-3 | RXFP1 Agonist and Anti-Fibrotic Relaxin Mimetic
Product Description
B7-33 is a single-chain relaxin mimetic peptide that functions as a selective agonist of the relaxin family peptide receptor 1 (RXFP1). It was rationally designed to mimic the biological actions of human relaxin-2 (H2 relaxin), a peptide hormone known for its potent anti-fibrotic, vasodilatory, and cardioprotective properties.
Unlike natural H2 relaxin, which is a two-chain peptide connected by disulfide bridges, B7-33 adopts a simplified single-chain structure. This modification enhances its synthetic stability, cost-efficiency, and bioavailability, while maintaining receptor selectivity.
Structural and Functional Background
Relaxin signaling through RXFP1 regulates fibrosis, inflammation, and tissue remodeling. The B7-33 peptide was developed to retain the beneficial effects of relaxin but minimize its complexity and off-target effects. By selectively activating the pERK1/2 pathway instead of the canonical cAMP pathway, B7-33 achieves targeted anti-fibrotic outcomes without triggering hormonal side effects.
B7-33 has demonstrated efficacy in reducing fibrosis, improving cardiac function, and promoting endothelial repair across several preclinical models.
Key Research Applications
Anti-Fibrotic Studies: Inhibits myofibroblast differentiation, decreases collagen synthesis, and reverses established fibrosis.
Cardioprotection: Enhances myocardial recovery following ischemic injury, attenuates remodeling, and reduces cardiac hypertrophy.